Ingalls & Snyder LLC trimmed its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 7.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 711,680 shares of the company's stock after selling 59,662 shares during the period. Ingalls & Snyder LLC's holdings in Kenvue were worth $15,194,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the stock. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Kenvue in the fourth quarter valued at approximately $128,000. Van ECK Associates Corp boosted its stake in Kenvue by 2.7% in the fourth quarter. Van ECK Associates Corp now owns 20,069,238 shares of the company's stock valued at $428,478,000 after acquiring an additional 518,988 shares in the last quarter. Focus Financial Network Inc. boosted its stake in Kenvue by 10.5% in the fourth quarter. Focus Financial Network Inc. now owns 11,529 shares of the company's stock valued at $246,000 after acquiring an additional 1,095 shares in the last quarter. Summit Trail Advisors LLC boosted its stake in Kenvue by 60.4% in the fourth quarter. Summit Trail Advisors LLC now owns 17,651 shares of the company's stock valued at $377,000 after acquiring an additional 6,646 shares in the last quarter. Finally, Principle Wealth Partners LLC boosted its stake in Kenvue by 3.7% in the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company's stock valued at $303,000 after acquiring an additional 500 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of research firms have issued reports on KVUE. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a "buy" rating to a "hold" rating and decreased their price target for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Citigroup decreased their price target on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a report on Wednesday, January 15th. Piper Sandler raised shares of Kenvue from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Finally, Barclays decreased their price target on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a report on Friday, January 17th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $23.00.
Get Our Latest Report on Kenvue
Kenvue Stock Performance
KVUE traded up $0.49 on Friday, reaching $21.94. The stock had a trading volume of 27,015,716 shares, compared to its average volume of 13,018,513. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The business's 50-day moving average price is $21.32 and its two-hundred day moving average price is $22.07. The company has a market cap of $42.07 billion, a P/E ratio of 41.40, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Sell-side analysts forecast that Kenvue Inc. will post 1.05 earnings per share for the current year.
Kenvue Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.74%. Kenvue's dividend payout ratio (DPR) is 154.72%.
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Articles
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
